Cronos Group Inc (CRON)
NASDAQ • Healthcare
August 6, 2026 at 20:00 UTC
About Cronos Group Inc
Cronos Group Inc. is a NASDAQ-listed healthcare company that develops cannabinoid products for therapeutic and recreational use, spanning cannabis cultivation, production, and commercialization. In FY2025, the company recorded $193.4 million in revenue. Its portfolio ranges from hemp-derived wellness and beauty products to dried cannabis formats, oils, and extracts sold under consumer brands.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Cronos Group Inc's Technical Indicators Summary
CRON shows constructive internals with price sitting modestly above short and medium moving averages while also clearing the 200-day averages, and OBV registering positive accumulation. Momentum measures are modestly positive and the MACD shows a small bullish reading, while RSI and CCI are neutral-to-favorable, indicating steady momentum rather than excess. Trend strength remains subdued with a low ADX and volatility is contained given a small ATR, and the classic pivot sits essentially at the current price. Technical takeaway: Strong Buy — trend and volume favor the upside with moderate momentum and low volatility supporting the stance.
| Indicator | Value |
|---|---|
RSI (14) | 57.76 |
Stochastic %K (14, 3, 3) | 66.51 |
CCI (20) | 96.85 |
WPR (14) | -24.29 |
Momentum (10) | 0.06 |
MFI | 77.40 |
MACD Level (12, 26) | 0.03 |
Bollinger Bands | $2.70 - $2.89 |
ATR (14) | $0.07 (2.56%) |
ADX (14) | 16.59 |
OBV | 57,098,029 |
Classic Pivot Point | $2.85 |
Fibonacci Pivot Point | $2.85 |
Simple Moving Averages | $2.65 - $2.83(5 indicators) |
Exponential Moving Averages | $2.66 - $2.83(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
With the sector roughly unchanged (0.00%), broader headwinds or tailwinds are limited. Exceptional liquidity has arrived, as volume spikes to 3.48× the regular run rate. CRON tops Q2 estimates with record net revenue and EBITDA as international markets drive growth.
Trading Volume
Above 10d avg 1.5M
5.1M
vs S&P 500 Today
Strong Outperformance
+12.82%
52-Week Position
Upper range
71.7%
Updated: August 6, 2026 at 19:18 UTC